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Blastic plasmacytoid dendritic cell neoplasm (BPDCN)  is a rare andaggressive hematologic malignancy for which there is still no effec-tive therapy. In order to identify genetic alterations useful for a new
treatment design, we used whole-exome sequencing to analyze 14
BPDCN patients and the patient-derived CAL-1 cell line. The functional
enrichment analysis of mutational data reported the epigenetic regulato-
ry program to be the most significantly undermined (P<0.0001). In par-
ticular, twenty-five epigenetic modifiers were found mutated (e.g.
ASXL1, TET2, SUZ12, ARID1A, PHF2, CHD8); ASXL1was the most fre-
quently affected (28.6% of cases). To evaluate the impact of the identi-
fied epigenetic mutations at the gene-expression and Histone H3 lysine
27 trimethylation/acetylation levels, we performed additional RNA and
pathology tissue-chromatin immunoprecipitation sequencing experi-
ments. The patients displayed enrichment in gene signatures regulated
by methylation and modifiable by decitabine administration, shared
common H3K27-acetylated regions, and had a set of cell-cycle genes
aberrantly up-regulated and marked by promoter acetylation.
Collectively, the integration of sequencing data showed the potential of
a therapy based on epigenetic agents. Through the adoption of a preclin-
ical BPDCN mouse model, established by CAL-1 cell line xenografting,
we demonstrated the efficacy of the combination of the epigenetic drugs
5’-azacytidine and decitabine in controlling disease progression in vivo. 
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ABSTRACT
Introduction
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
is a rare malignancy derived from precursors of plasma-
cytoid dendritic cells.1-4 It has no clear racial or ethnic
predisposition and more often affects elderly males
(male/female ratio 3.3:1; mean/median age at diagnosis:
61-67 years). BPDCN patients usually respond to first-
line chemotherapy, but despite this they almost invari-
ably relapse and display a dismal prognosis with a medi-
an overall survival (OS) ranging from 10 to 19 months.2
No standardized therapeutic approach has so far been
established for BPDCN, even if hematopoietic stem cell
transplantation has been shown to achieve remission in
selected patients.5-6 Therefore, the development of effec-
tive treatments still represents an unmet need.7 The
pathobiology of BPDCN is poorly understood and the
number of reports exploring its molecular features is still
limited.8-21  Recent advances in the understanding of the
BPDCN molecular landscape have paved the way for
novel treatment approaches based on the inhibition of
the BCL2 protein,22 the activation of the cholesterol
efflux,23 the repression of the Bromodomain-containing
protein 4 (BRD4),24 and binding to the interleukin-3
receptor (IL3R).25 All these potential therapeutic options
(which are worthy of further evaluation) have mainly
emerged from the analysis of the BPDCN transcriptome
or from its antigenic repertoire. The genomic landscape
of BPDCN has not been well investigated, and only a
few studies have explored the mutational events occur-
ring in BPDCN, mainly through targeted sequencing
approaches.14,16,19,20 
Unfortunately, these have not offered any novel
prospects of treatment options.
In this study, we performed whole-exome sequencing
(WES) of 14 BPDCN samples and of the BPDCN-derived
CAL-1 cell line to look for specific BPDCN genetic vulner-
abilities that may support the design of new therapeutic
strategies. The WES mutational findings were comple-
mented by copy number variant (CNV) analysis, RNA and
pathology tissue-chromatin immunoprecipitation (PAT-
ChIP) sequencing results. The integration of data allowed
us to identify a successful combinatorial therapy based on
epigenetic drugs able to control disease progression in a
rapidly progressive BPDCN xenograft model.
Methods 
Blastic plasmacytoid dendritic cell neoplasm samples
We collected 14 BPDCN cryopreserved cutaneous biop-
sies at diagnosis, 9 matched saliva samples and the
BPDCN patient-derived cell line, CAL-1. The pathological
cases were evaluated as previously described17 and diag-
nosed by experienced hematopathologists (CA, EB, FF, LC,
MP, ES, CT, MT, and SAP) according to  World Health
Organization diagnostic criteria.2 Informed consent was
obtained from each patient in accordance with the Ethical
Review Board of the Department of Experimental,
Diagnostic, and Specialty Medicine of the University of
Bologna, Italy, and the Declaration of Helsinki. DNA was
extracted as reported in the Online Supplementary
Appendix. The main clinical, immunohistochemical and
cytogenetic features of the BPDCN patients are shown in
Online Supplementary Tables S1 and S2.
Whole-exome sequencing analysis
We performed paired-end sequencing of matched
tumor/normal DNA samples (9 cases), tumor only DNA
samples (5 cases), and the CAL-1 cell line (Online
Supplementary Table S3) using the TruSeq Exome Kit and
Nextera Rapid Capture Exome kit (Illumina). Further details
are available in the Online Supplementary Appendix. 
Sanger sequencing
We used Sanger sequencing to analyze two candidate
nonsense somatic mutations of SUZ12 and ASXL1 occurring
in 2 patients, respectively, as described in the Online
Supplementary Appendix.
Targeted sequencing
We performed MiSeq targeted sequencing (Illumina) of
the 14 BPDCN tumor patients, 7 normal matched saliva
samples and the CAL-1 cell line, already analyzed by WES.
More bioinformatics details are provided in the Online
Supplementary Appendix and Online Supplementary Tables S4
and S5.
RNA sequencing analysis
Five BPDCN cases studied by WES and targeted sequenc-
ing had sufficient material for RNA extraction and sequenc-
ing; these samples represented the RNA sequencing (RNA-
seq) discovery set. We also collected an additional 4 BPDCN
cryopreserved cutaneous biopsies, sufficient only for RNA
sequencing experiments, used as an RNA-seq extension set.
RNA of 4 normal plasmacytoid dendritic cell (pDCs) sam-
ples was purchased from AllCells (Alameda, CA, US) and
used for comparison. For details, see Online Supplementary
Table S6 and the Online Supplementary Appendix.
Pathology tissue-chromatin immunoprecipitation
sequencing
The BPDCN_25 and BPDCN_37 patients were provided
with one skin biopsy: half was cryopreserved and used for
WES, targeted and RNA sequencing analysis, and the other
half was fixed in formalin, included in paraffin and used for
pathology tissue-chromatin immunoprecipitation (PAT-
ChIP) sequencing analysis. PAT-ChIP experiments were per-
formed as in Fanelli et al.26 Further details are available in the
Online Supplementary Appendix.
CAL-1 cell line
CAL-1, a BPDCN cell line27 was cultured as reported pre-
viously.18 The CAL-1 gene expression profile of a previous
study was used17 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE62014).
Mouse model and in vivo treatments
Experiments were carried out on 6-8-week old non-
obese diabetic severe combined immunodeficient
NOD/SCID interleukin-2 receptor g (IL-2Rg)–null (NSG)
mice, as previously reported.13 All animal experiments
were carried out in accordance with the Italian laws in
force (Legislative Decree 26/14 and subsequent amend-
ments) and institutional guidelines. All in vivo studies were
ratified by the Italian Ministry of Health. For induction of
BPDCN in mice, 5000 CAL-1 cells were injected intra-
venously (i.v.) through the lateral tail vein in non-irradiat-
ed mice. Engrafted mice were then treated with borte-
zomib, 5’-azacytidine, decitabine and romidepsin, as
detailed in the Online Supplementary Appendix.
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Figure 1. The genomic characterization of blastic plasmacy-
toid dendritic cell neoplasm (BPDCN). (A) Circos plot graphi-
cal representation of the functional analysis performed on
54 genes recurrently mutated and/or affected by nonsense
and frameshift single nucleotide variants (SNVs) in BPDCN
whole-exome sequencing (WES) samples. The four biological
processes most significantly enriched are reported in the
counterclockwise order from the highest to the lowest 
P-value: the gamma-aminobutyric acid (GABA) secretion (in
violet), the Rac signaling (in red), the hematopoietic stem cell
homeostasis (in light blue) and the epigenetic process (in
green). The genes are colored according to their belonging to
one or more of the biological processes represented. Genes
not involved are in gray. (B) Overview of the TET2 and ASXL1
mutations identified. Structure of ASXL1 protein with C-termi-
nal plant homeodomain catalytic region and structure of
TET2 protein showing the catalytic core region: the cysteine-
rich (Cys) and double-stranded β-helix (DSBH) domains.
Empty circles: somatic SNVs. + : frameshift SNV; *nonsense
SNV. (C) Heatmap representation of SNVs in BPDCN WES
samples and its distribution among selected pathways com-
monly mutated in myeloid disorders. The SNVs, the affected
genes and the related pathways are reported in rows, while,
the BPDCN samples are in columns.
A
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Results
Whole-exome sequencing reveals the epigenetic pro-
gram dysregulation as the main theme of the blastic
plasmacytoid dendritic cell neoplasm mutational 
landscape
We collected 14 BPDCN cases with a mean age of 56
years at diagnosis (range 9-89 years), a male-to-female
ratio of 10:4, and the classical BPDCN presentation (Online
Supplementary Tables S1 and S2).1 The enrolled patients
underwent different treatment regimens and 78.5% (11
out of 14) died of the disease 6.3-76 months after the diag-
nosis or were lost at follow up. Most patients who under-
went autologous and/or allogeneic hematopoietic stem
cell transplantation experienced a prolonged survival. 
We performed WES on 14 BPDCN cases, and on the
M.R. Sapienza et al.
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Figure 2. The transcriptome and H3K27 trymethylation/acetylation profiling of blastic plasmacytoid dendritic cell neoplasm (BPDCN). (A) Unsupervised hierarchi-
cal clustering performed on 5 BPDCN samples and 4 plasmacytoid dendritic cell (pDCs) samples according to the expression level of the RNA sequencing data. In
the heat-map each row represents a gene and each column a sample. The color scale exemplifies the relative expression level of a gene across all samples: (red)
represented genes with an expression level above the mean; (blue) the genes with an expression level lower than the mean. Tumors (BPDCNs) and controls (pDCs)
cluster in two distinct groups. (B) Gene Set Enrichment Analysis (GSEA) plot illustrating the enrichment of the KDM5B and PRMT5 gene signatures in BPDCN patients
reported in literature34-36 as well as the enrichment of a set of genes, described by Missiaglia et al.37 as responsive to hypomethylating treatment, namely decitabine.
Normalized enrichment score (NES) ≥ 2; false discovery rate (FDR) q-value false discovery rate ≤0.0001. (C) Visualization of anti-H3K27ac and anti-H3K27me3 nor-
malized pathology tissue-chromatin immunoprecipitation (PAT-ChIP)  sequencing profiles in the UCSC Genome Browser showing genomic regions from patient
BPDCN_25 and BPDCN_37. (Red boxes) Exemplificative regions displaying a similar level of anti-H3K27ac in both patients. (Black solid rectangles) Genes in corre-
spondence of the anti-H3K27ac peaks. (D) The cases BPDCN_25 and BPDCN_37 share common H3k27ac regions. (E) Histogram representation of the top 10 sig-
nificant biological processes emerged by Gene Ontology (GO) analysis of 86 up-regulated genes marked by H3K27ac in their promoters. GO categories are shown
in x-axis and the fold enrichment values of observed versus expected genes are reported in the y-axis (FDR q-value <0.001). 
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Figure 3. The efficacy of epigenetic agents in a preclinical blastic plasmacytoid dendritic cell neoplasm (BPDCN) mouse model. (A) Pharmacodynamic assessment
of the percentage of human CD56+CD38+ cells in the peripheral blood (PB), bone marrow (BM) of the femur and spine, spleen, and liver of a representative vehicle-
treated BPDCN mouse model, 39 days after CAL-1 injection. The cytofluorometric assays shows the tumor dissemination in all the tissues analyzed. (B) Hematoxylin
& eosin (H&E) staining of BM and spleen samples collected in a representative vehicle-treated NSG mouse 39 days after CAL-1 injection (H&E; x400; Olympus DP2-
SAL). The histological assay shows a marked dissemination of blast elements. The immunohistochemistry detection of the CD303 (BDCA-2) antigen, in the murine
BM, indicates the presence of specific BPDCN blasts cells (Immmuno-alkaline phosphatase; Gill’s hematoxylin nuclear counterstaining; x400; Olympus DP2-SAL).
These results further confirmed the effective engraftment of CAL-1 cell line. (C) Graphical representation of the treatment schedules observed in a BPDCN mouse
model. Each treatment is represented by a single color or by a combination of colors and was administered for four weeks as follows: 5’-azacytidine 5 mg/kg 5 doses
at 2-day intervals (green), decitabine 2.5 mg/kg 3 doses at 2-day intervals (light brown), romidepsin 0.5 mg/kg every day (violet), bortezomib 0.5 mg/kg two times
weekly (fuchsia). The same doses were also administered in various combinations. (D) Kaplan-Meier curves comparing overall survival of BPDCN mice models respec-
tively treated with vehicle or the above reported treatments. Each treatment is summarized by a box colored as described above. *Indicates that the combination of
decitabine and 5’-azacytidine was the most effective in prolonging mice survival. Curves were compared by log-rank test, n=5 mice/treatment arm. (E)
Pharmacodynamic assessment of spleen size in 4 representative NSG mice CAL-1 injected after 39 days of treatment with vehicle (mouse Control), Decitabine
(mouse Deci), 5’-azacytidine (mouse Aza), and 5’-azacytidine plus decitabine (mouse Deci+Aza) according to the dosing schedule reported above. ns: not significant. 
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BPDCN patient-derived CAL-1 cell line and identified
1302 non-synonymous single nucleotide variants (SNVs)
represented predominantly by missense SNVs (n=1251),
nonsense SNVs (n=47), and frameshift insertions/dele-
tions (n=7). To verify the robustness of the WES analysis,
2 randomly-selected variants occurring in the ASXL1 and
SUZ12 genes, respectively, were validated by Sanger
sequencing (Online Supplementary Figure S1). To extend the
validation to a higher number of samples and mutations,
a targeted sequencing approach was adopted: 21 SNVs
were interrogated by MiSeq Illumina technology in the
same BPDCN cases analyzed by WES and a concordance
of 95.2% (20 out of 21 SNVs) was achieved, underlining a
high consistency of data (Online Supplementary Table S7).
The 1302 non-synonymous SNVs detected by WES affect-
ed 1166 genes, all but 7 known to be related with patho-
logical conditions and reported as mutated in the
Catalogue of Somatic Mutations in Cancer
(COSMIC_v66).
To identify the biological processes that were most
altered by the mutational events, we performed a func-
tional enrichment analysis of the 9 genes that were recur-
rently mutated (≥ 3 samples) and the 45 genes impacted
by deleterious (nonsense or frameshift) SNVs. Among
the top 10 significantly enriched biological processes, the
epigenetic program was the most represented
(P=0.0001), followed by hematopoietic stem cell home-
ostasis, Rac signaling and gamma-aminobutyric acid
(GABA) secretion (Figure 1A and Online Supplementary
Table S8). The ASXL1 gene proved to be the most fre-
quently mutated (28%, 4 out of 14 samples), followed by
TET2 (21%, 3 out of 14 samples); both genes displayed
mainly nonsense or frameshift SNVs located within or
upstream of the catalytic domain of the proteins, poten-
tially leading to their functional disruption (Figure 1B and
Online Supplementary Table S9). We consulted the Gene
Ontology database28 to identify among the 1166 BPDCN
mutated genes those implicated in the epigenetic regula-
tion. We found 25 mutated epigenetic modifier genes
controlling chromatin accessibility (ARID1a, CHD8,
SMARCA1), DNA methylation (TET2, IDH2), or histone
post-transcriptional modifications [methylation (ASXL1,
SUZ12, MLL family), demethylation (KDM4D), acetyla-
tion (EP300, EP400), ubiquitination (PHC1, PHC2),
dephosphorylation (EYA2), and exchange (SRCAP)]. Of
note, 12 out of 14 BPDCN samples (86%) harbored at
least one of the 25 epigenetic regulator genes mutated,
and specifically 8 out of 14 patients (57.14%) presented
a deleterious lesion (nonsense/frameshift SNV) (Online
Supplementary Table S10). Many SNVs clustered in the
histone methylation pathway, specifically in genes
belonging to the Polycomb-repressive complex 2
(ASXL1, ASXL3, SUZ12) and in histone methyltrans-
ferases (ASHL1, SETMAR, MLL), possibly compromising
the integrity of the methylation program. Besides genetic
lesions targeting epigenetic regulators, we also detected
mutations potentially affecting molecular programs com-
monly deregulated in myeloid malignancies, such as RAS
signaling29 (hot-spot SNVs on KRAS or NRAS, alterna-
tively), DNA repair/cycle progression30 (SNVs on BRCA1,
ATM, ATR, and RAD52), Wnt-signaling31 (SNVs on
WNT3, WNT7B, WNT10 and BCL9L), cell growth32 (SNVs
on RUNX2, MAPK1), and splicing machinery33 (an SNV
on ZRSR2) (Figure 1C). 
Whole-exome sequencing data were also used for
cytogenetic CNV analysis, which highlighted extensive
losses along the chromosome 9 and the associated dele-
tion of the tumor suppressor CDKN2A gene in 8 out of
14 BPDCN samples (57%) (Online Supplementary Figure
S2), as already reported in the literature.12,15,20 In addition,
CNV analysis showed that deletions affected six of the
nine genes recurrently mutated; deletions were always
mutually exclusive with mutations (Online Supplementary
Figure S3). However, no significant correlation was found
between genetic lesions and the clinical data.
Blastic plasmacytoid dendritic cell neoplasm tran-
scriptome profiling confirms the dysregulation of epi-
genetic programs
Genetic lesions in key epigenetic modifier genes and in
related regulatory networks can induce profound pertur-
bations in the transcriptional homeostasis of the cell. To
further substantiate the impact of mutations affecting
the chromatin remodeling pathway in BPDCN, we per-
formed RNA sequencing of 5 BPDCNs, considered as the
discovery set, already studied by WES and MiSeq target-
ed sequencing. We compared the patients' transcrip-
tomes with those of 4 normal plasmacytoid dendritic cell
(pDC) samples isolated from the peripheral blood of
healthy individuals and used as controls. BPDCN tumor
samples and pDCs segregated separately according to
their gene expression profiles (Figure 2A). Two thousand
and thirty-four genes (2034) were significantly deregulat-
ed among patients, and approximately half of them were
up-regulated (46%) in the BPDCN setting. Gene set
enrichment analysis (GSEA) reported the significant
deregulation of two genetic signatures involved in the
methylation process, driven by the KDM5B34 histone
demethylase and PRMT535 methyltransferase-associat-
ed genes, respectively. Of note, GSEA also detected the
significant enrichment of a set of genes associated with
the response to a DNA demethylating agent,36 namely
decitabine (Figure 2B). The GSEA results [normalized
enrichment score (NES) ≥2; false discovery rate (FDR) q-
value ≤0.0001] were then validated in an extension set of
4 BPDCN samples and in a CAL-1 cell line (Online
Supplementary Figures S4 and S5).
Genome-wide ChIP-sequencing substantiates 
epigenetic dysregulation of cell cycle program 
in blastic plasmacytoid dendritic cell neoplasms
To investigate if the transcriptional deregulation of
BPDCNs could be linked to specific epigenetic features,
we analyzed the histone acetylation/methylation pro-
files of 2 selected BPDCN patients (BPDCN_25 and
BPDCN_37). The trimethylation at lysine 27 of histone 3
(H3K27me3) is closely associated with inactive gene pro-
moters, while its acetylation (H3K27ac) closely correlates
with gene activation, the two epigenetic modifications
being mutually exclusive. Given this, we analyzed the
genome-wide distribution of trimethylation and acetyla-
tion profiles of H3K27 in BPDCN cases. The analysis of
PAT-ChIP sequencing data demonstrated that the 2
patients converged on the same pattern of histone acety-
lation, sharing as much as 43.6% of the acetylated pro-
moters (Figure 2C and D). PAT-ChIP sequencing results
were then integrated into the RNA sequencing data lead-
ing to the identification of a signature of 86 genes
marked by promoter acetylation and significantly over-
expressed in the BPDCN RNA sequencing sets. Gene
M.R. Sapienza et al.
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Ontology analysis of the 86 selected genes highlighted
the enrichment in biological processes involved in cell
cycle progression (FDR q-value <0.001) (Figure 2E and
Online Supplementary Table S11).
In vivo blastic plasmacytoid dendritic cell neoplasm
modeling demonstrates combined epigenetic therapy
as effective in controlling disease progression
The integration of results obtained from WES, RNA
sequencing and PAT-ChIP-sequencing experiments clear-
ly pointed to a fundamental role for epigenetic dysregu-
lation in BPDCN and allowed us to hypothesize that this
malignancy could display susceptibility to drugs active
on the epigenetic regulation. Following the demonstra-
tion that the CAL-1 cell line, like primary BPDCN sam-
ples, had mutations clustering in chromatin remodeling
pathway (Figure 1C) and enrichment in the same epige-
netic programs (Online Supplementary Figure S5), we
developed an in vivo CAL-1 xenograft BPDCN-like model
to explore the effects of treatments targeting the acetyla-
tion, methylation, and also the NF-kB pathways, accord-
ing to previous results.17,18 To this end, we focused on
four different 
FDA-approved compounds: 5’-azacytidine, decitabine,
romidepsin and bortezomib.
NSG mice intravenously injected with 5x103 CAL-1
cells rapidly developed a systemic BPDCN-like progres-
sive disease, which was defined by the flow cytometry
identification of human CD56+CD38+ malignant cells in
the peripheral blood, bone marrow, spleen and liver, as
evaluated at 39 days after injection (Figure 3A). The
pathological infiltration by malignant BPDCN cells in the
mouse model was also confirmed at the same time point
by the histopathological analysis of the bone marrow
and spleen samples, which showed the presence of atyp-
ical cells with blastic morphology and expressing the
human CD303/BDCA2 pDC marker (Figure 3B).
Xenografted mice were divided into 11 treatment groups
(n=110 mice) one day after CAL-1 injection and treated
with either saline or with the hypo-methylating agents
5’-azacitidine or decitabine, the proteasome inhibitor
bortezomib, and the histone deacetylase inhibitor
romidepsin, used as single agents or in combination,
according to the treatment schedule summarized in
Figure 3C. The administration of 5’-azacytidine and
decitabine used as single agents significantly prolonged
OS of the mice when compared with saline (median sur-
vival 43.6 days vs. 32 days, P<0.01 for 5’-azacytidine;
median survival 44.7 days vs. 32 days, P<0.05 for
decitabine) while neither bortezomib nor romidepsin
alone showed beneficial effects on disease outcome.
When the same agents were associated in combined
treatment experiments, three different combinations
were seen to significantly prolong mouse survival: i)  the
association of romidepsin and decitabine (median sur-
vival 42.8 days vs. 32 days, P<0.05); ii) the combination
of romidepsin, decitabine, and 5’-azacytidine (median
survival 41.8 days vs. 32 days, P<0.01); and iii) the asso-
ciation of decitabine and 5’-azacytidine (median survival
52.8 days vs. 32 days, P<0.01), which achieved the best
result in terms of survival (Figure 3D). Consistently, 5’-
azacytdine and decitabine administered alone reduced
the CAL-1-induced splenomegaly as evaluated at day 39
post injection and their combination proved to be even
more effective (Figure 3E).
Discussion
Blastic plasmacytoid dendritic cell neoplasm is a rare
myeloid malignancy with dismal prognosis and no stan-
dard therapy. In the present study, we performed WES on
the largest series of BPDCNs that, to the best of our
knowledge, has so far been reported in the literature.
Thanks to the integration of WES with RNA and PAT-
ChIP sequencing, we provide new insights into BPDCN
pathobiology by highlighting the dysregulation of the epi-
genetic program as a hallmark of the disease and suggest
possible novel therapeutic interventions.
We found BPDCN patients extensively affected by
mutations of genes involved in the epigenetic regulation:
25 epigenetic modifiers were mutated in almost all
BPDCN patients (13 out of 14) and the CAL-1 cell line. In
more than half of the patients (8 out of 14), the mutations
heralded damaging functional alterations (Figure 1C).
Some of the mutated genes have already been reported in
previous studies (e.g. ASXL1, RAS, ATM, ARID1A, and
IDH2), although, at times, at different rates than in our
series (see ASXL1 and TET2, which were found to be
mutated in 28.6% and 21.4% of our samples vs. 32% and
36% of those of Menezes et al.19). In this respect, it should
be remembered that the aim of our study was not only to
extensively explore the mutational landscape of BPDCN,
but also to possibly translate molecular notions into a pre-
clinical approach. In any case, thanks to the employment
of a WES approach, which did not limit our investigation
to a priori-selected genes, we recognized additional mutat-
ed epigenetic factors that have never been described
before but which are potentially relevant in the context of
BPDCN, like PHF2 histone demethylase, that enhances
the TP53-tumor suppressor activity,37 and the CHD8
Chromodomain helicase DNA-binding protein-8, that
promotes the E2F-dependent transcription and cell cycle
progression.38 Besides the epigenetic pathway, we also
detected mutations affecting programs common to other
myeloid malignancies, such as DNA repair process,30
Wnt/β-catenin signaling,31 and the differentiation path-
way.32
Importantly, the functional enrichment analysis of WES
data showed that among all genes/pathways explored the
epigenetic program was the most deregulated (P<0.0001).
To evaluate the impact of the identified epigenetic
mutations at gene expression level, we analyzed the tran-
scriptome of samples studied by WES. Among up-regulat-
ed genes, GSEA revealed the significant enrichment of
two methylation pathways, driven respectively by the
KDM5B histone-demethylase34 and by the PRMT5 argi-
nine methyltransferase-5;35 these two epigenetic modifiers
are reported to be over-expressed in several cancer types
and also represent promising therapeutic targets.39
Blockade of the PRMT5 activity reduces cell survival in
chronic myelogenous leukemia40 and inhibition of
KDM5B demethylation correlates with cell growth arrest
in hepatocellular carcinoma and breast cancers.41,42  We also
identified the overexpression of one gene signature36
specifically responsive to the administration of the
hypomethylating agent decitabine; a molecular finding
bearing important therapeutic implications (FDR q=1.85E-
5). To gain a functional insight into the epigenetic land-
scape of BPDCN samples, we performed PAT-ChIP
sequencing of H3K27-acetylation/trymethylation signals
of 2 BPDCN patients. The trimethylation of H3K27 marks
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inactive gene promoters and enhancers, while its acetyla-
tion correlates with gene activation.43 PAT-ChIP sequenc-
ing data showed that the 2 patients converged on the
same epigenetic pattern sharing approximately half of the
identified H3K27-acetylated promoters. Interestingly, the
common acetylated regions comprised 10 super-
enhancers (SE) bound by the Bromodomain-containing
protein 4 (BRD4), as described by Ceribelli et al. in a recent
work on BPDCN (data not shown).24
The integration of PAT-ChIP and the RNA sequencing
data highlighted a set of 86 genes involved in the cell-cycle
progression aberrantly over-expressed and marked by
H3K27-promoter acetylation. This finding suggests that
the cell-cycle deregulation could be driven by H3K27-
acetylation signals, a hypothesis meriting future ad hoc
studies that could help to clarify the mechanism of prolif-
eration of this largely obscure disease.
The rarity of the disease (with an incidence of
0.000045%) and its extremely aggressive behavior (OS 10-
19 months) limits the number of available patients includ-
ed in biological and/or clinical studies. For these reasons,
not surprisingly, BPDCN is still an orphan tumor lacking a
standardized and effective therapeutic approach. In the
last few years, new molecular studies have opened the
way to innovative target therapies (e.g. bortezomib,17,18
venetoclax,22 BET-inhibitors,24 SL-40125) being used in
clinical trials. Some of these are showing promising
results, although still concerns remain regarding their safe-
ty. Of note, all the treatments proposed are mainly the
result of investigation into the RNA transcriptome, while
the DNA features of BPDCN patients have barely been
evaluated. 
We therefore decided  to tackle this yet incurable dis-
ease by designing the first therapeutic strategy modeled
on the DNA mutational status of BPDCN patients, ana-
lyzed by WES. The WES mutational findings enhanced by
the RNA and PAT-ChIP sequencing results clearly evi-
denced the prominent role of the epigenetic program dys-
regulation among BPDCN patients and guided  our thera-
peutic approach towards the use of epigenetic agents. In
particular, we tested in vivo the efficacy of US Food and
Drug Administration-approved epigenetic drugs which
could be considered for potential repositioning in clinical
trials: two hypomethylating agents such as decitabine and
5’-azacytidine, and the histone deacetylase inhibitor
romidepsin. We hypothesized that these drugs could
impact on tumor progression because: i) BPDCN patients
displayed potential sensitivity to hypomethylating agents,
particularly to decitabine, as detected by GSEA analysis;
ii) both 5’-azacytidine and decitabine are currently used
for the treatment of myelodysplastic syndromes,44,45 which
are myeloid neoplasms sharing many epigenetic mutated
genes with BPDCN; iii) preclinical studies on several
malignancies demonstrated that the action of decitabine is
synergized by romidepsin.46 In the light of this, our exper-
imental design focused on epigenetic drugs with a large-
scale activity, aiming to explore whether we might induce
cell death by perturbation of the malignant epigenetic pro-
gramme. In addition to the epigenetic drugs, we also veri-
fied the efficacy of bortezomib, a proteasome inhibitor,
which had previously been shown to significantly induce
in vitro and in vivo BPDCN cell death.17,18 Our experiments
revealed that the treatment with 5’-azacytidine in combi-
nation with decitabine significantly inhibits disease pro-
gression and extends survival (P<0.01) in a preclinical
mouse model. In the past, two reports experimented the
use of  5’-azacytidine in elderly BPDCN patients, though
this therapeutic choice was not yet sustained by a molec-
ular rationale.47,48 Here we demonstrate that 5’-azacytidine
is more effective in tumor eradication when combined
with decitabine. Further studies are ongoing to elucidate
the synergistic mechanisms between the two drugs.
In conclusion, we have identified the deregulation of the
epigenetic program as a genetic hallmark of BPDCN and
suggest a novel therapeutic approach based on the combi-
nation of two hypomethylating agents, 5’-azacytidine and
decitabine, to be tested in future clinical trials.  
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